CABA
Cabaletta Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$632.63M
P/E Ratio
—
EPS
$-2.10
Beta
3.17
52W High
$4.23
52W Low
$1.26
50-Day MA
$3.15
200-Day MA
$2.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of T-cell therapies designed for patients with B-cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-170.60M |
| Operating Margin | 0.00% |
| Return on Equity | -127.00% |
| Return on Assets | -61.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.11 |
| Price-to-Book | 5.66 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $163.05M |
| Float | $97.56M |
| % Insiders | 1.06% |
| % Institutions | 51.11% |
Historical Volatility
HV 10-Day
161.32%
HV 20-Day
120.68%
HV 30-Day
108.97%
HV 60-Day
94.17%
HV Rank
60.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($13.12 target)
1
Strong Buy7
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/11/2026